Summary | |
---|---|
Symbol | CKMT1B |
Name | creatine kinase, mitochondrial 1B |
Aliases | UMTCK; CKMT |
Chromosomal Location | 15q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Mitochondrion inner membrane; Peripheral membrane protein; Intermembrane side. |
Domain |
PF00217 ATP PF02807 ATP |
Function |
Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa. |
Biological Process |
GO:0006600 creatine metabolic process |
Molecular Function |
GO:0004111 creatine kinase activity GO:0016775 phosphotransferase activity, nitrogenous group as acceptor |
Cellular Component |
GO:0005743 mitochondrial inner membrane |
KEGG |
hsa00330 Arginine and proline metabolism hsa01100 Metabolic pathways |
Reactome | - |
Summary | |
---|---|
Symbol | CKMT1B |
Name | creatine kinase, mitochondrial 1B |
Aliases | UMTCK; CKMT |
Chromosomal Location | 15q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CKMT1B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | CKMT1B |
Name | creatine kinase, mitochondrial 1B |
Aliases | UMTCK; CKMT |
Chromosomal Location | 15q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CKMT1B in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CKMT1B |
Name | creatine kinase, mitochondrial 1B |
Aliases | UMTCK; CKMT |
Chromosomal Location | 15q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CKMT1B in various data sets.
|
Points in the above scatter plot represent the mutation difference of CKMT1B in various data sets.
|
Summary | |
---|---|
Symbol | CKMT1B |
Name | creatine kinase, mitochondrial 1B |
Aliases | UMTCK; CKMT |
Chromosomal Location | 15q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CKMT1B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CKMT1B |
Name | creatine kinase, mitochondrial 1B |
Aliases | UMTCK; CKMT |
Chromosomal Location | 15q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CKMT1B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CKMT1B. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CKMT1B |
Name | creatine kinase, mitochondrial 1B |
Aliases | UMTCK; CKMT |
Chromosomal Location | 15q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CKMT1B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CKMT1B |
Name | creatine kinase, mitochondrial 1B |
Aliases | UMTCK; CKMT |
Chromosomal Location | 15q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CKMT1B expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CKMT1B |
Name | creatine kinase, mitochondrial 1B |
Aliases | UMTCK; CKMT |
Chromosomal Location | 15q15 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CKMT1B and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |